In primary drug-resistant T-cell acute lymphoblastic leukemia (T-ALL) cells, the researchers observed that ARV-825 eradicated cells through BRD4 protein degradation, significantly reducing c-Myc expression.518 Crews’s team also developed ARV-771 (219), another PROTAC molecule featuring VHL as the E3 ligase ligand, which efficiently degrades BRD4 protein in prostate cancer cells, exhibiting a potency of BRD2/3/4 degradation in various prostate cell lines below 5 nM (Table 4). The gene discussed is BRD4; the disease is prostate carcinoma.